JOP20240182A1 - تحضير مثبطات تيروزين كيناز من بروتون - Google Patents

تحضير مثبطات تيروزين كيناز من بروتون

Info

Publication number
JOP20240182A1
JOP20240182A1 JOJO/P/2024/0182A JOP20240182A JOP20240182A1 JO P20240182 A1 JOP20240182 A1 JO P20240182A1 JO P20240182 A JOP20240182 A JO P20240182A JO P20240182 A1 JOP20240182 A1 JO P20240182A1
Authority
JO
Jordan
Prior art keywords
proton
preparation
tyrosine kinase
kinase inhibitors
compound
Prior art date
Application number
JOJO/P/2024/0182A
Other languages
Arabic (ar)
English (en)
Inventor
Ngoc Duc Tran
Thomas Joachim Landewald Rammeloo
Christos Xiouras
Philippe Fernandes
Edward Cleator
William Marc Maton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of JOP20240182A1 publication Critical patent/JOP20240182A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JOJO/P/2024/0182A 2022-02-18 2024-08-14 تحضير مثبطات تيروزين كيناز من بروتون JOP20240182A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20220100151 2022-02-18
EP22167032 2022-04-06
EP22178413 2022-06-10
PCT/EP2023/054043 WO2023156599A1 (en) 2022-02-18 2023-02-17 Synthesis of bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
JOP20240182A1 true JOP20240182A1 (ar) 2024-08-14

Family

ID=85227338

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0182A JOP20240182A1 (ar) 2022-02-18 2024-08-14 تحضير مثبطات تيروزين كيناز من بروتون

Country Status (13)

Country Link
US (1) US20250163076A1 (enExample)
EP (1) EP4479405A1 (enExample)
JP (1) JP2025506671A (enExample)
KR (1) KR20240148351A (enExample)
AU (1) AU2023221549A1 (enExample)
CA (1) CA3252338A1 (enExample)
CL (1) CL2024002409A1 (enExample)
CO (1) CO2024011229A2 (enExample)
IL (1) IL314902A (enExample)
JO (1) JOP20240182A1 (enExample)
MX (1) MX2024010134A (enExample)
PE (1) PE20242069A1 (enExample)
WO (1) WO2023156599A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023025459A2 (pt) 2021-06-04 2024-02-27 Janssen Pharmaceutica Nv Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CA3252338A1 (en) 2023-08-24
CL2024002409A1 (es) 2025-01-03
PE20242069A1 (es) 2024-10-18
MX2024010134A (es) 2024-08-27
EP4479405A1 (en) 2024-12-25
CO2024011229A2 (es) 2024-08-30
JP2025506671A (ja) 2025-03-13
IL314902A (en) 2024-10-01
US20250163076A1 (en) 2025-05-22
KR20240148351A (ko) 2024-10-11
AU2023221549A1 (en) 2024-10-03
WO2023156599A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CO2024011229A2 (es) Síntesis de inhibidores de tirosina quinasa de bruton
JOP20230310A1 (ar) مثبطات كيناز التيروسين للبروتون وطرق استخدامها
MX2025007434A (es) Compuesto con anillo fusionado de pirazol, metodo de preparacion y uso del mismo
DK1362047T3 (da) Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2023007265A (es) Inhibidores de cdk y su uso como productos farmacéuticos.
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2024013215A (es) Compuestos para inhibir kif18a
BR112022018828A2 (pt) Derivados de benzodiazepina como gaba a gamma1 pams
EA202190880A1 (ru) Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MX2024008462A (es) Inhibidores de inmunooncología mek y usos terapéuticos de estos.
CL2025002125A1 (es) Compuestos novedosos
CO2025018750A2 (es) Inhibidores de wrn
MX2025001765A (es) Derivados deuterados de pirimidin-2-il sulfonamida
JOP20250299A1 (ar) المركبات السبيرو ماكروسيكلية الناهضة لمستقبِل الأوركسين 2
EA202191995A1 (ru) Циклические молекулы в качестве ингибитора тирозинкиназы брутона
MX2025009371A (es) Forma cristalina de derivado de sulfonamida y metodo de preparacion para ello
PH12022552342A1 (en) The rad51 inhibitor compound 67a (2301085-06-1) at a specific dosage for treating cancer
MX2022010675A (es) Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
WO2019182746A3 (en) Catalyst formulations
CR20230448A (es) Inhibidores de vmat2 y métodos de uso
ATE380810T1 (de) Protein-tyrosine-kinase-inhibitoren
EA202092114A1 (ru) Новый способ получения спрингена